

Special Issue

Omics Approaches on Immune-Mediated Inflammatory Diseases: Towards Novel Biomarkers and Potential Therapeutic Targets Vol. 2

Message from the Guest Editor

Recent technological advances facilitated high-throughput omics approaches (genomics, transcriptomics, epigenomics, proteomics, and metabolomics) for the evaluation of critical molecular compartments involved in the development and perpetuation of chronic immune-mediated inflammatory diseases (IMIDs). Unveiling key players governing their pathogenesis and progression may pave the way for the detection of novel biomarkers for disease prognosis and response-to-therapy monitoring, while suggesting potential therapeutic targets. Bulk and single-cell omics, multi-omics flow cytometry, new-generation microscopy, and systems biology are among the current approaches expected to provide useful tools to be applied in the daily clinical practice, for the improvement of patients' management and quality of life. After the success in collecting significant number of valuable manuscripts, our Special Issue is now launching its second volume, aiming at hosting more original research, review, or systematic review articles describing the most recent advances in the field of omics on IMIDs, possibly suggesting novel biomarkers and/or therapeutic targets.

Guest Editor

Dr. Maria-Ioanna Christodoulou

1. Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus
2. School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK

Deadline for manuscript submissions

closed (28 February 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/147736

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).